(PDF) P1.01-05 Metformin in Combination With Crizotinib for

P1.01-05 Metformin in Combination With Crizotinib for the Treatment of EML4-ALK+ Lung Cancer

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.561

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P2.01-89 Synergistic Cytotoxicity Through MAPK/ERK Pathway and ALK Inhibition in Crizotinib Resistant EML4-ALK-Positive Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer

European Journal of Cancer

Cancer Research

English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

Multidisciplinary

English

A Case Report of an EML4-ALK-positive Elderly Non-Small Cell Lung Cancer Patient With a Poor PS Successfully Treated With Crizotinib

Japanese Journal of Lung Cancer

Respiratory Medicine

English

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.01-53 Local Treatment for Oligoprogression/Oligometastases After Failure to Crizotinib for ALK-Rearranged Stage IV Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Development of Aseptic Renal Abscess in a Patient With Non-Small-Cell Lung Cancer With ALK Translocation During Crizotinib Treatment

Advances in Lung Cancer

English

Outcomes of ALK Positive Lung Cancer Patients Treated With Crizotinib or Second-Generation ALK Inhibitor: A Monoinstitutional Experience

English